Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab for moderate to severe hidradenitis suppurativa in adults and adolescents
NL-OMON61128Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Lutikizumab with Placebo (2 arms). Primary endpoint: HiSCR 75 at Week 16. Started Apr 2025; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON61128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61128.